All articles by Divya Tirumalaraju

  1. UK MHRA probes fake Covid-19 medical products

    The Medicines and Healthcare products Regulatory Agency (MHRA) of the UK has launched an investigation into 14 cases of fake…
    Read More…

    6 Apr
  2. XBiotech and BioBridge to develop plasma-based Covid-19 therapy

    Biopharmaceutical firm XBiotech has partnered with non-profit BioBridge Global to develop a Covid-19 therapy using natural antibodies from convalescent plasma…
    Read More…

    6 Apr
  3. Servier agrees to acquire Symphogen

    French pharmaceutical company Servier has signed a definitive agreement to acquire 100% shares in Danish therapeutic antibody discovery firm Symphogen….
    Read More…

    6 Apr
  4. GSK partners with Innovax Biotech on Covid-19 vaccine

    GlaxoSmithKline (GSK) has partnered with Xiamen Innovax Biotech to support the development of a recombinant protein-based vaccine candidate against Covid-19….
    Read More…

    6 Apr
  5. Izana starts compassionate use study of potential Covid-19 drug

    UK-based Izana Bioscience has launched a compassionate use study of namilumab (IZN-101) in patients with rapidly worsening Covid-19 in Bergamo…
    Read More…

    6 Apr
  6. Large-scale trial for coronavirus drugs launches in UK

    The UK Government has announced that a large-scale randomised trial has been launched to assess potential treatments for Covid-19 (coronavirus)….
    Read More…

    6 Apr
  7. Study finds anti-parasitic drug could kill coronavirus in 48 hours

    Researchers from Biomedicine Discovery Institute (BDI) at Monash University in Australia have found that an anti-parasitic drug called Ivermectin could…
    Read More…

    6 Apr
  8. Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs

    Vir Biotechnology and Alnylam Pharmaceuticals have expanded their multi-target infectious diseases alliance to include up to three targets for SARS-CoV-2,…
    Read More…

    3 Apr
  9. FluGen, Bharat Biotech and UW–Madison partner on Covid-19 vaccine

    Vaccine development companies FluGen and Bharat Biotech have partnered with the University of Wisconsin–Madison (UWMadison) to develop and evaluate a…
    Read More…

    3 Apr
  10. Kite licences Teneobio’s multiple myeloma targeting antibodies

    Gilead unit Kite has signed a licence and collaboration agreement with Teneobio for sole rights to antibodies intended for the…
    Read More…

    3 Apr
Close
Close
Close

Go Top